KT 009Alternative Names: KT009; Recombinant growth factor - Kunovus Technologies
Latest Information Update: 26 May 2017
$50 / €47 *
At a glance
- Originator Kunovus Technologies
- Class Growth factors
- Mechanism of Action Protein replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Intervertebral disc degeneration
Most Recent Events
- 26 May 2017 KT 009 is available for licensing as of 26 May 2017.
- 26 May 2017 Preclinical trials in Intervertebral disc degeneration before May 2017 (Bio-Link Australia pipeline, May 2017)